Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00471536 · BASELINE

Baseline characteristics

Pazopanib in Treating Patients With Metastatic Urothelial Cancer · Source last updated 2014-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      19
    units
    Participants
groups
  1. description
    Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Treatment (Enzyme Inhibitor Therapy)
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          42
          upper Limit
          80
          value
          66
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          5
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          14
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          14
      title
      United States
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      Korea, Republic of
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Hong Kong
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Australia
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      19
    units
    Participants
groups
  1. description
    Patients receive 800 mg oral pazopanib hydrochloride once daily on days 1-28. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
    id
    BG000
    title
    Treatment (Enzyme Inhibitor Therapy)
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          lower Limit
          42
          upper Limit
          80
          value
          66
    dispersion Type
    FULL_RANGE
    param Type
    MEDIAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          5
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          14
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          14
      title
      United States
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      Korea, Republic of
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Hong Kong
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          2
      title
      Australia
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice